clinical-application

Bone Scan (Tc-99m MDP)

Whole-body scintigraphy using technetium-99m methylene diphosphonate (or HDP) — sensitive for osseous metastatic disease, stress fractures, osteomyelitis, Paget's disease, avascular necrosis. Remains the workhorse bone imaging study despite growing NaF PET/CT use in high-volume centers.

Clinical pathway

  1. IV injection of 20–30 mCi Tc-99m MDP.
  2. Three-hour uptake period — patient encouraged to hydrate and void before imaging.
  3. Whole-body planar imaging — anterior + posterior, 10–15 min scan time.
  4. SPECT or SPECT/CT of area of interest — spine, pelvis, skull as indicated.
  5. Reporting — photopenic and hypermetabolic foci, superscan pattern in diffuse metastatic disease.

Typical systems

SPECT/CT resolves scintigraphic foci against anatomy — standard of care for indeterminate planar findings.

Room + procedure characteristics

Related